Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 8/20 | 0.52 |
| ▸ | MMP9 | P14780 | 7/20 | 0.52 |
| ▸ | PPARG | P37231 | 9/20 | 0.41 |
| ▸ | PPARD | Q03181 | 9/20 | 0.41 |
| ▸ | PPARA | Q07869 | 9/20 | 0.41 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.39 |
| ▸ | MMP12 | P39900 | 1/20 | 0.39 |
| ▸ | MMP3 | P08254 | 1/20 | 0.39 |
| ▸ | F10 | P00742 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7618075 | 0.86 | MMP9 (0.52) | MMP2MMP9 | |
| SCHEMBL5592398 | 0.84 | MMP2 (0.43) | MMP2MMP9MMP12MMP3 | |
| SCHEMBL8997318 | 0.77 | MMP3 (0.41) | LTB4R2MMP12MMP3F10 | |
| SCHEMBL7784104 | 0.77 | CA12 (0.43) | MMP2MMP9MMP12 | |
| SCHEMBL12933668 | 0.74 | MMP9 (0.54) | MMP2MMP9MMP12MMP3 | |
| SCHEMBL9754526 | 0.74 | MMP9 (0.54) | MMP2MMP9MMP12MMP3 | |
| SCHEMBL9614222 | 0.73 | MMP2 (0.43) | MMP2MMP9PPARGPPARA | |
| SCHEMBL1890167 | 0.72 | MMP9 (0.37) | MMP2MMP9MMP12 | |
| SCHEMBL27348452 | 0.72 | SOAT1 (0.40) | MMP2MMP9MMP12F10 | |
| SCHEMBL9318602 | 0.71 | CYSLTR2 (0.42) | MMP2MMP9PPARGPPARDPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6441023-B1 | FOR THERAPY OF ARTHRITIS, TUMOR METASTASIS, TISSUE ULCERATION, ABNORMAL WOUND HEALING, PERIODONTAL DISEASE, BONE DISEASE, DIABETES (INSULIN RESISTANCE) AND HIV INFECTION | AMERICAN HOME PRODUCTS CORPORATION | 2002-08-27 | — | — | US | disclosed |
| US-20020032186-A1 | N-hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors | AMERICAN CYANAMID COMPANY (US) | 2002-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020032186-A1 | N-hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors | MMP12, ADAM33, MMP2 | MMP2 3/4885MMP9 13/4885PPARG 1679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.